Synagis®: Sign-up to become a Thrive Advocate

To get more information about the Thrive Network, just fill out the form below. The Thrive Network is exclusively funded by MedImmune and operated by Health Advocacy Strategies at MedImmune's direction. After you sign up, representatives from Health Advocacy Strategies will contact you about joining Thrive.

The Thrive Network and MedImmune, Inc. respect your privacy. The information you provide on this form will remain confidential and will be used only by the Thrive Network and its agents. The information will not be used for solicitations or provided or sold to other parties. Please review our Privacy Policy for more information.

All fields are required.

Contact Info

First Name

Last Name

Address 1

Address 2 (optional)

City

State

ZIP:

E-mail

Phone number

( )

What is the best way for us to contact you?

Phone

E-mail

US Postal Mail

My Baby

Month/Year of child's birth:
(or expected date)

(Sample: mm/yyyy)

Number of weeks pregnancy at birth?

How did you hear about Thrive?

Thrive brochure

Friend or healthcare professional

The internet

Additional Options

I would also like to sign up for the Helping HandSM program.

I am also willing to participate in market research about RSV and related products and services.

You can unsubscribe or update your information at any time.

The program is designed to support parents of babies on Synagis throughout RSV season.

If you are willing to participate, MedImmune and its agents will only use the information for internal research and will not sell or share your personal information with outside companies.

Important Safety Information

Synagis® (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.